Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

New Self-Sealing Needle Prevents Blood Loss in Those with Bleeding Disorders

XTALKS VITALS NEWS

Injection

For those with bleeding disorders – including hemophilia – an injection using a standard needle could result in an uncontrolled loss of blood.

Share this!

October 28, 2016 | by Sarah Hand, M.Sc.

Most patients experience a minimal amount of bleeding after receiving an injection. But for those with bleeding disorders – including hemophilia – an injection using a standard needle could result in an uncontrolled loss of blood.

Researchers in Korea have developed a novel biodegradable polymer, which can be used to coat the needle and effectively seal an injection site. The research was published in the journal, Nature Materials.

“Bleeding is largely unavoidable following syringe needle puncture of biological tissues and, while inconvenient, this typically causes little or no harm in healthy individuals,” said the researchers in their publication. “However, there are certain circumstances where syringe injections can have more significant side effects, such as uncontrolled bleeding in those with hemophilia, coagulopathy, or the transmission of infectious diseases through contaminated blood.”



According to the Centers for Disease Control and Prevention (CDC), it’s estimated that 20,000 people in the US are living with hemophilia. The bleeding disorder results from a deficiency, or total lack of, the clotting factors necessary to prevent uncontrolled bleeding.

The majority of people with hemophilia are diagnosed at a very young age, with some of the most severe forms being identified in patients as young as one month. Approximately two thirds of cases of the bleeding disorder – for which there is no known cure – occur in people with a family history of the disease.

The polymer developed by the Korean researchers is derived from chitosan, a component of crustacean shells. The gel polymer hardens upon contact with blood to prevent post-injection bleeding.

The researchers compared the polymer-coated needles to regular needles in mouse models of hemophilia. All of the mice injected with standard needles died as a result of uncontrolled bleeding. Those who were injected with the polymer-coated needles however, saw a 100 percent survival rate.

So far, the coated needles have only been tested in preclinical studies, but the promising results have the potential to apply to human patients as well. “Such self-sealing haemostatic needles and adhesive coatings may therefore help to prevent complications associated with bleeding in more clinical settings,” said the researchers.


Keywords: Hemophilia, Injection, Animal Model


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.